Helen Fasanya-Uptagraft, MD
Gastroenterology · Omaha, NENPI 1598920415
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 38.1% of the total. Reporting peaked in 2019 at $8,561 and has fallen 76.5% since, to $2,016 in 2025. Among gastroenterology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 530 payments — averaging $49.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$10K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- AbbVie$2K
- Johnson & Johnson$967
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$862
- Gilead$688
- plus $3K from 32 others
Across 47 payments — averaging $2438.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$115K
What the payments were for
- Consulting fees$9,55036%
- Speaking & faculty fees$6,69026%
- Travel & lodging$6613%
- Food & beverage$9,25835%
- Other$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $9,985 |
| Takeda Pharmaceuticals U.S.A., Inc. | 74 | $8,510 |
| AbbVie(2 entities) | 128 | $2,076 |
| Johnson & Johnson | 70 | $967 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 49 | $862 |
| Gilead | 29 | $688 |
| Bristol Myers Squibb | 34 | $532 |
| Sanofi | 14 | $441 |
| Madrigal Pharmaceuticals | 23 | $329 |
| QOL Medical, LLC | 18 | $295 |
| Pfizer | 17 | $169 |
| Lilly USA, LLC | 7 | $167 |
| Merck | 9 | $144 |
| Amgen | 5 | $108 |
| Intercept Pharmaceuticals, Inc. | 6 | $102 |
| Regeneron Healthcare Solutions, Inc. | 4 | $97 |
| Ardelyx, Inc. | 5 | $94 |
| Aimmune Therapeutics, Inc. | 2 | $93 |
| Ironwood Pharmaceuticals, Inc | 5 | $88 |
| Janssen Scientific Affairs, LLC | 1 | $73 |
| Boehringer Ingelheim | 2 | $50 |
| Phathom Pharmaceuticals, Inc. | 4 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Covidien LP | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Heron Therapeutics, Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Welch Allyn | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Organon | 1 | $13 |
| Baxter Healthcare | 1 | $13 |
| UCB, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,189 in reported general payments places this provider in the 90th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 44 | $1,208,776 |
| Skyrizi On-BodyRisankizumab-Rzaa | 11 | $246,589 |
| Humira PenAdalimumab | 12 | $96,389 |
| XifaxanRifaximin | 12 | $39,230 |
| LinzessLinaclotide | 33 | $24,843 |
| Colestipol Hcl | 74 | $9,017 |
| Mesalamine | 23 | $4,252 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 140 | $3,194 |
| Budesonide DrBudesonide | 22 | $3,188 |
| Pantoprazole Sodium | 226 | $2,198 |
| Lubiprostone | 12 | $1,639 |
| Famotidine | 80 | $1,151 |
| Esomeprazole Magnesium | 18 | $1,021 |
| Ursodiol | 12 | $920 |
| Dicyclomine Hcl | 44 | $651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $967 | $1,208,77644 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $862 | $39,23012 claims |
| AbbVieLinzess | $2,076 | $24,84333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 gastroenterology providers in Nebraska.
Other gastroenterology in Omaha
- Benjamin HallOmaha$154K
- Sandeep MukherjeeOmaha$145K
- Rowen ZettermanOmaha$119K
- Derrick EicheleOmaha$54K
- Joshua EvansOmaha$34K
- Michael SchaferOmaha$30K
- Peter MannonOmaha$30K
- Rajani RangrayOmaha$15K
- Grant HutchinsOmaha$15K
- Trevor PearsonOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.